Major BD Reset: Protagonist Therapeutics Restructures Takeda Partnership Around Rusfertide
A significant partnership restructuring has just taken place in the hematology space.
www.linkedin.com/posts/boston...
#BCIC #Biotech #Takeda #ProtagonistTherapeutics #Rusfertide #Hematology #PharmaDeals
For patients with #PolycythemiaVera, #rusfertide provided durable, sustained hematocrit control that stayed below 43% and reduced #phlebotomy requirements up to 52 weeks, with 61.9% of patients remaining ineligible for phlebotomy between 0-52 weeks: https://ow.ly/KYiZ50XKVRT
#HemeSky #MedSky
🏆 Big moment for MPNs: PV research took the plenary stage at #ASCO2025. Dr. Andrew Kuykendall presented VERIFY trial results on rusfertide:
✓ 62% maintained Hct <45%
✓ Better symptom control
✓ Fewer skin malignancies
#MPNs #PVawareness #Rusfertide #VERIFYtrial
Als "practice changing" wurde die Phase-3-Studie VERIFY auf dem #ASCO2025 bewertet. Darin erreichte #Rusfertide zur Therapie der Polycythaemia vera sowohl den primären Endpunkt als auch wichtige sekundäre Endpunkte.
#SilenceTherapeutics more p3 #rusfertide polycythemia vera data presented by competitor Protagonist+Takeda at ASCO, incl number of phlebotomies and % <45% hematocrit.
#SLN124 compares favorably in earlier studies.
finance.yahoo.com/news/protago...
#Hepcidin agents set to improve #PolycythemiaVera care (blog): rnaitherapeutics.blogspot.com/2025/03/hepc...
$PTGX $SLN $IONS #rusfertide #divesiran #sapablursen
Good news is that #rusfertide did not cause imbalance in cancer...as had been concern following earlier uncontrolled studies.
Turns out, it's the cytoreductive agents (often oral small mol) #polycythemiavera patients are taking. It kills me when people scaremonger about #CRISPR-related cancer risk.
